15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Eledon Pharmaceuticals Inc, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $8.00 to $12.00, a moderate spread. The average target of $10.00 sits 181% above the current $3.56. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.18 next quarter toward $-0.72 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Eledon Pharmaceuticals Inc.
As of Jul, 3 of 3 firms rate ELDN a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ELDN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.18
Range $-0.20 – $-0.16 · 4 analysts · -12% YoY
Next period, 4 analysts expect Eledon Pharmaceuticals Inc to earn $-0.18 a share (range $-0.20 – $-0.16), versus $-0.21 a year earlier. Full-year consensus is $-0.87, growing to $-0.72 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 4 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Eledon Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ELDN.
#1
PS
Pete Stavropoulos
Cantor Fitzgerald · Rank #232
Buy
No targeton ELDN
Overall win rate
34%
+ Follow
#2
Yi Chen
HC Wainwright & Co. · Rank #238
Buy
$9.00+152.5% to target
Overall win rate
34%
+ Follow
#3
Thomas Smith
Leerink Partners
Buy
$8.00+124.4% to target
Coverage
—
+ Follow
#4
SS
Seema Sheoran
Rodman & Renshaw
Buy
$12.00+236.6% to target
Coverage
—
+ Follow
#5
AL
Albert Lowe
Craig-Hallum
Buy
No targeton ELDN
Coverage
—
+ Follow
ELDN stock forecast FAQ
What is ELDN's average 12-month price target?+
The 2 analysts with a live target average $10.00 for Eledon Pharmaceuticals Inc over the next 12 months, ranging from a $12.00 high to a $8.00 low.
Is ELDN stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ELDN?+
The Street-high target is $12.00 (Rodman & Renshaw), and the Street-low is $8.00 (Guggenheim). The average of all 2 active targets is $10.00.
How many Wall Street analysts cover ELDN?+
3 analysts have an active rating on Eledon Pharmaceuticals Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering ELDN?+
Among analysts who currently cover ELDN, Pete Stavropoulos of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #232). Their current call is Buy.
What is Eledon Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.18 per share (range $-0.20 – $-0.16) across 4 analysts. Full-year EPS is projected at $-0.87, rising to $-0.72 the following year.
How much revenue is Eledon Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ELDN lately?+
As of Jul, 3 of 3 firms rate ELDN a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ELDN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
